Takeaway
Case study of a patient with anti-IgLON5 disease reveals an absence of brainstem tau pathology and a neuropathologic profile consistent with moderate Alzheimer’s disease (AD).
Why this matters
Anti-IgLON5 is a novel neurodegenerative disease associated with antibodies against the neuronal cell-adhesion protein IgLON5, and is characterized by sleep disturbance, gait instability and bulbar symptoms.
Brainstem tauopathy was documented in the first case of anti-IgLON5, yet there is uncertainty as to whether this is a typical neuropathologic feature of the disease.